ARISTOTLE HF Subgroup Outcome Index (proxy – ABC-based)

ARISTOTLE HF Subgroup Outcome Index: Rationale and clinical context The original ARISTOTLE trial (apixaban vs warfarin) and its biomarker substudies showed that age, a clinical history of heart failure, and circulating biomarkers — notably NT-proBNP, high-sensitivity cardiac troponin, and growth differentiation factor-15 (GDF-15) — were among the strongest predictors of death and heart-failure related events in patients with atrial fibrillation. The ABC (Age, Biomarkers, Clinical history) risk framework was developed from ARISTOTLE data to quantify mortality risk in anticoagulated AF patients; this calculator implements a transparent proxy based on that approach to provide a relative HF-outcome index. For precise absolute risk estimates, one should use the original ABC equations or the published online ABC calculator (model coefficients/baseline hazard).